AWAiden X. Wang

Aiden X. Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aiden X. Wang has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Generalizable Strategies for the Synthesis of Cereblon‐Recruiting PROTAC Prodrugs

    by Aiden X. Wang, Bin Liu, Elise M. Ackerman, Yichen Xiang, Hung V.‐T. Nguyen, Yivan Jiang, Angela N. Koehler, Jeremiah A. Johnson

    Cereblon (CRBN)‐recruiting PROTACs (proteolysis‐targeting chimeras) are among the most clinically advanced degraders but remain challenging to chemically modify for translation to prodrug‐based delivery strategies. Here, we report three orthogonal approaches—triazole quaternization, tertiary‐amine alkylation, and installation of a hydroxyl linker—that enable chemoselective, high‐yielding syntheses of CRBN‐recruiting PROTAC prodrugs. These strategies allow incorporation of self‐immolative linkers whose cleavage kinetics can be predictably tuned to release the parent PROTAC, which is demonstrated in the context of PEGylated macromonomer and bottlebrush prodrug macromolecular scaffolds. In multiple myeloma models, representative PROTAC‐bottlebrush prodrugs (PROTAC‐BPDs) induce cellular potency profiles that follow the designed PROTAC release rates, confirming that the observed protein degradation and cytotoxicity arise from effective prodrug linker cleavage. Collectively, this work establishes generalizable approaches for constructing prodrugs of CRBN‐based PROTACs, expanding the synthetic space for targeted protein degradation and providing new design principles for controlling degrader activation, selectivity, and in vivo delivery.

  • Open Access

    Generalizable Strategies for the Synthesis of Cereblon‐Recruiting PROTAC Prodrugs

    by Aiden X. Wang, Bin Liu, Elise M. Ackerman, Yichen Xiang, Hung V.‐T. Nguyen, Yivan Jiang, Angela N. Koehler, Jeremiah A. Johnson

    Cereblon (CRBN)‐recruiting PROTACs (proteolysis‐targeting chimeras) are among the most clinically advanced degraders but remain challenging to chemically modify for translation to prodrug‐based delivery strategies. Here, we report three orthogonal approaches—triazole quaternization, tertiary‐amine alkylation, and installation of a hydroxyl linker—that enable chemoselective, high‐yielding syntheses of CRBN‐recruiting PROTAC prodrugs. These strategies allow incorporation of self‐immolative linkers whose cleavage kinetics can be predictably tuned to release the parent PROTAC, which is demonstrated in the context of PEGylated macromonomer and bottlebrush prodrug macromolecular scaffolds. In multiple myeloma models, representative PROTAC‐bottlebrush prodrugs (PROTAC‐BPDs) induce cellular potency profiles that follow the designed PROTAC release rates, confirming that the observed protein degradation and cytotoxicity arise from effective prodrug linker cleavage. Collectively, this work establishes generalizable approaches for constructing prodrugs of CRBN‐based PROTACs, expanding the synthetic space for targeted protein degradation and providing new design principles for controlling degrader activation, selectivity, and in vivo delivery.

  • Open Access

    Antibody–bottlebrush prodrug conjugates for targeted cancer therapy

    by Bin Liu, Hung V.-T. Nguyen, Yivan Jiang, Aiden X. Wang, Valerie Lensch, Zehao Sun, Zane H. Boyer, Philip A. Raftopoulos, Yutong Dai, Piper L. MacNicol, et al.

    Antibody–drug conjugates (ADCs) are effective targeted therapeutics but are limited in their ability to incorporate less-potent payloads, varied drug mechanisms of action, different drug release mechanisms and tunable drug-to-antibody ratios. Here we introduce a technology to overcome these limitations called ‘antibody–bottlebrush prodrug conjugates’ (ABCs). An ABC consists of an IgG1 monoclonal antibody covalently conjugated to the terminus of a compact bivalent bottlebrush prodrug that has payloads bound through cleavable linkers and polyethylene glycol branches. This design enables the synthesis of ABCs with tunable average drug-to-antibody ratios up to two orders of magnitude greater than those of traditional ADCs. We demonstrate the functional flexibility and manufacturing efficiency of this technology by synthesizing more than 10 different ABCs targeting either HER2 or MUC1 using drugs with potencies spanning several orders of magnitude as well as imaging agents for ABC visualization and photocatalysts for proximity-based labeling of the ABC interactome. ABCs display high target engagement, high cell uptake and improved efficacy in tumor models compared to conventional HER2-targeted ADCs, suggesting promise for clinical translation.


  • Open Access

    Antibody–Bottlebrush Conjugates Unlock Diverse Payloads for Targeted Cancer Therapy

    by Bin Liu, Hung Nguyen, Yivan Jiang, Aiden Wang, Valerie Lensch, Zehao Sun, Zane Boyer, Philip Raftopoulos, Yutong Dai, Piper MacNicol, et al.

    Antibody drug conjugates (ADCs), which feature a monoclonal antibody (mAb) for cell targeting linked to a cytotoxic payload for cell killing, are a remarkably effective class of targeted therapeutics. Despite their success, however, ADCs typically rely on highly potent payloads, precluding the use of less potent payloads and a broader range of payload mechanisms of action (MoA).1-4 Moreover, the emerging perspective that passive targeting mechanisms play roles in ADC function in vivo suggests opportunities to engineer new ADCs based on stable prodrug scaffolds with tunable release mechanisms.5,6 Here, inspired by the physics, shape, and chemical versatility of molecular bottlebrush polymers,7-11 we introduce “Antibody–Bottlebrush prodrug Conjugates” (ABCs) as a next-generation targeted cancer therapy platform designed to enable the modular and predictable use of a broad range of payloads with varied potencies and MoAs. ABCs feature an IgG1 mAb covalently conjugated to the terminus of a compact bivalent bottlebrush prodrug (BPD) with payloads bound via cleavable linkers and hydrophilic poly(ethylene glycol) (PEG) branches on each repeat unit. This design enables the synthesis of ABCs with tunable drug-to-antibody ratios (DARs) up to two orders-of-magnitude greater than traditional ADCs without negatively impacting the physical properties of the mAb. The efficiency of ABC manufacturing is highlighted by the synthesis of >10 different variants for distinct targets (HER2 and MUC1) and with payload potencies spanning several orders-of-magnitude, imaging agents for direct ABC visualization, and photocatalysts for proximity-based labeling of the ABC interactome. ABCs display excellent target engagement, cell uptake, and efficacy in antigen expressing tumor-bearing mouse models, suggesting that they may be promising for future clinical translation.

  • Open Access

    An organometallic swap strategy for bottlebrush polymer–protein conjugate synthesis

    by Bin Liu, Jacob Rodriguez, Landon J. Kilgallon, Wencong Wang, Yuyan Wang, Aiden Wang, Yutong Dai, Hung V.-T. Nguyen, Bradley L. Pentelute, Jeremiah A. Johnson

    Conjugates of proteins and bottlebrush polymers are prepared using an “organometallic swap” strategy.


  • Open Access

    Design of a Novel Gene Therapy Construct to Achieve Sustained Brain-Derived Neurotrophic Factor Signaling in Neurons

    by Andrew Osborne, Aiden X.Z. Wang, Alessia Tassoni, Peter S. Widdowson, Keith R. Martin

    Brain-derived neurotrophic factor (BDNF) acting through the tropomyosin-related receptor-B (TrkB) is an important signaling system for the maintenance and survival of neurons. Gene therapy using either recombinant adeno-associated virus (AAV) or lentiviral vectors can provide sustained delivery of BDNF to tissues where reduced BDNF signaling is hypothesized to contribute to disease pathophysiology. However, elevation in BDNF at target sites has been shown to lead to a downregulation of TrkB receptors, thereby reducing the effect of chronic BDNF delivery over time. A novel gene sequence has been designed coding both the ligand (BDNF) and the TrkB receptor in a single transgene separated by a short viral-2A sequence. The single transgene is efficiently processed intracellularly in vitro and in vivo to yield the two mature proteins, which are then independently transported to their final cellular locations: TrkB receptors to the cell surface, and BDNF contained within secretory vesicles. To accommodate the coding sequences of both BDNF and TrkB receptors within the narrow confines of the AAV vectors (4.7 kb pairs), the coding region for the pro-domain of BDNF was removed and the signal peptide sequence modified to improve production, intracellular transport, and secretion of mature BDNF (mBDNF). Intracellular processing and efficacy was shown in HEK293 cells and SH-SY5Y neuroblastoma cells using plasmid DNA and after incorporating the TrkB-2A-mBDNF into an AAV2 vector. Increased BDNF/TrkB-mediated intracellular signaling pathways were observed after AAV2 vector transfection while increased TrkB phosphorylation could be detected in combination with neuroprotection from hydrogen peroxide–induced oxidative stress. Correct processing was also shown in vivo in mouse retinal ganglion cells after AAV2 vector administration to the eye. This novel construct is currently being investigated for its efficacy in animal models to determine its potential to progress to human clinical studies in the future.